Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Lloyds launches new injection to reduce treatment time for breast cancer patients

A new injection that reduces treatment time for women with HER2 positive breast cancer, is now being administered to patients in LloydsPharmacy healthcare centres in Cardiff, Wales and Newcastle, England, the pharmacy chain announced on Thursday (May 27).

Working with local NHS Trusts, LloydsPharmacy Clinical Homecare is one of the first healthcare providers to be administering the recently approved Phesgo injection in a community-based setting, helping to bring care closer to home for metastatic breast cancer patients and significantly reduce treatment time.


Rhiannon Walter-Davies, principal pharmacist at Velindre Cancer Centre said: “We are always exploring ways in which we can widen and improve cancer treatment options for our current and future patients and our partnership with LloydsPharmacy Clinical Homecare supports us in that vision.

“For more people than ever, cancer has become a long-term condition rather than an acute disease, and our priority is to provide safe and effective care whilst ensuring patient choice is at the heart of our service. So many of our patients have already benefited from receiving care closer to home and we look forward to many more experiencing improved health outcomes now that we are able to administer this innovative new injection in a community-based setting.”

Healthcare Centre

The new breast cancer treatment, which is administered by a LloydsPharmacy Clinical Homecare oncology nurse, was initially introduced at the LloydsPharmacy Healthcare Centre in Cardiff, which is a partnership between Velindre Cancer Centre and Tenovus Cancer Care.

It is now also available at the LloydsPharmacy Healthcare Centre in Newcastle, with Royal Surrey and Scunthorpe clinics launching in the coming months.

The Phesgo injection, developed by manufacturer Roche, is a newly combined remedy of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase. This was previously given as separate intravenous infusions, it is now being delivered as a single subcutaneous injection into a patient’s thigh in combination with intravenous chemotherapy.

More For You

RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less
Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less